{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-058979","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.045214+00:00","generated_at":"2026-05-24T10:38:24.362823+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyne Therapeutics appoints Erick Lucera as CFO; outgoing CFO Richard Scalzo to consult","bullets":["Erick Lucera named CFO and Treasurer, effective March 31, 2025; previously CFO of Editas Medicine and AVEO Pharmaceuticals.","Lucera receives base salary $520k, bonus up to 40%, and inducement equity: 214,500 stock options + 66,100 RSUs.","Richard Scalzo steps down as SVP Finance & Treasurer same date; will provide consulting services for up to 6 months.","Scalzo's unvested equity to continue vesting during consultancy; stock option exercise period extended to 6 months post-consulting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-058979","json":"https://secwatch.observer/filing/0001193125-25-058979.json","markdown":"https://secwatch.observer/filing/0001193125-25-058979.md","text":"https://secwatch.observer/filing/0001193125-25-058979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525058979/0001193125-25-058979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525058979/d788212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:38:24.362823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f83a84bcdf","claim":"Erick Lucera was appointed as Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc..","evidence_excerpt":"On March 20, 2025, Dyne Therapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had appointed Erick Lucera as Chief Financial Officer and Treasurer of the Company, effective as of March 31, 2025 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525058979/0001193125-25-058979-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}